F. Hoffmann-La Roche AG / Ionis Pharmaceuticals, Inc.

Alzheimer's disease and Huntington's disease (RNA-targeted / antisense)

6.7M US cases/yr · $13.0B Anti-amyloid MAb peak global sales analyst consensus (primary AD commercial benchmark) · 760 Roche-Ionis 2023 deal size (USD MM, $60M upfront + ~$700M milestones plus royalties)

Disease Overview

Alzheimer's disease (AD) affects approximately 6.7 million Americans aged 65 and over (Alzheimer's Association 2023 Facts and Figures), projected to reach 13.8 million by 2060, and is the seventh leading cause of US death. Huntington's disease (HD) is an ultra-rare autosomal dominant CAG-repeat neurodegenerative disorder with roughly 30,000 symptomatic US patients and a further 200,000 at genetic risk (Huntington's Disease Society of America). Across both indications the therapeutic landscape in 2023 was reshaped by anti-amyloid monoclonal antibody approvals — Leqembi (lecanemab, Eisai/Biogen) received accelerated approval January 2023 and traditional approval July 2023 — and by the high-profile failure of tominersen, Roche's anti-HTT antisense oligonucleotide co-developed with Ionis, which was discontinued in Phase 3 GENERATION-HD1 in 2021 for futility and reinitiated as lower-dose GENERATION-HD2 in 2022. RNA-targeted therapeutics (antisense oligonucleotides and siRNAs) remain the most direct approach for mutant HTT silencing and for non-amyloid AD targets such as tau (MAPT) and APOE. Ionis and Biogen's tofersen (Qalsody) received accelerated FDA approval in April 2023 for SOD1-ALS, validating the ASO platform in neurodegeneration and setting a commercial template for intrathecal ASO delivery in CNS disorders.

Competitive Landscape

RNA-targeted neurodegeneration is a crowded space with mixed clinical outcomes. Huntington's disease assets: tominersen (RG6042 / IONIS-HTTRx, Roche/Ionis) — anti-HTT ASO, halted in GENERATION-HD1 2021, reinitiated as GENERATION-HD2 in low-CAG-burden patients; WVE-003 (Wave Life Sciences) — allele-selective antisense targeting mutant HTT SNP; AMT-130 (uniQure) — AAV5-miHTT one-time gene therapy, Phase 1/2; PTC518 (PTC Therapeutics, partnered with Novartis 2024) — oral HTT splicing modulator. Alzheimer's RNA-targeted: BIIB080 / IONIS-MAPTRx (Biogen/Ionis) — anti-tau ASO Phase 2; ION582 (Ionis) — Angelman and broader CNS; anti-APOE programs at Alnylam, Biogen. AD broader market anchors: Leqembi (lecanemab, Eisai/Biogen) — approved 2023 passive anti-Abeta MAb; Kisunla (donanemab, Lilly) — approved July 2024; Aduhelm (aducanumab) — withdrawn. Non-RNA AD pipeline: E2814 (Eisai anti-tau MAb); posdinemab / JNJ-63733657 (J&J tau MAb); AL001 / latozinemab (Alector/GSK, FTD and AD). Ionis-Roche deal adds two undisclosed early-stage programs, signaling that RNA-targeting remains a credible path alongside MAbs despite tominersen's setback.